Top Tweets for #CCRCC
In Silico Gene Expression Profiling Maps the Drivers of Pan-Cancer Progression
https://t.co/BmXXY5Wlhe
By Mehwish Majeed and Muhammad Zurgham Akram
From IECC 2026 Conference
@MediPharma_MDPI
#PanCancer #DifferentialGeneExpression #PDAC #LUAD #HCC #ccRCC #LungAdenocarcinoma
𝗞𝗨𝗥𝗔 𝗣𝗥𝗘𝗦𝗘𝗡𝗧𝗔 𝗥𝗘𝗦𝗨𝗟𝗧𝗔𝗗𝗢𝗦 𝗗𝗘𝗟 𝗘𝗡𝗦𝗔𝗬𝗢 𝗙𝗔𝗦𝗘 𝟭𝗔 𝗣𝗔𝗥𝗔 𝗘𝗟 𝗖Á𝗡𝗖𝗘𝗥 𝗗𝗘 𝗥𝗜ÑÓ𝗡
@kuraoncology presenta datos prometedores del ensayo Fase 1a (FIT-001) en cáncer de riñón avanzado (#ccRCC):
🔸Tasa de respuesta: 33%–50%
🔸 Mediana PFS: 13 meses
🔸 Perfil de seguridad manejable
🔸 Fase 1b en reclutamiento (EE.UU./UE) hacia registro en 2028.
🔗Noticia completa: https://t.co/LDbiUuT16X
Can targeting tumor metabolism improve #ccRCC treatment?
This review highlights how #MetabolicReprogramming drives disease progression and reveals promising metabolic targets for precision therapy. @Ningbo_Uni
#GenesAndDiseases: https://t.co/aKi8Qc8RhE
Published in @NEJM: Phase 3 LITESPARK-022 shows improved disease-free survival with adjuvant pembrolizumab + belzutifan in #ccRCC after surgery. @elena_verzoni is among the authors, with @IstTumori at the forefront of advancing #adjuvant treatment.
https://t.co/Yt6VOcLrgF
@DrChoueiri @Nature @DanaFarber @DanaFarberNews @harvardmed @DrRanaMcKay @montypal @neerajaiims @VivekSubbiah @ASCO @myESMO @ASCOPres Congratulations @DrChoueiri and team on this high-impact paper in @Nature! 🎉 Exciting to see a novel HIF-2α inhibitor with compelling translational research published simultaneously. Big moment for the field! #ARC20 #ccRCC
💥 ¡Nueva aprobación de la FDA en carcinoma de células renales claras (#ccRCC)!
La FDA ha dado luz verde a la combinación de belzutifan + pembrolizumab como tratamiento adyuvante para pacientes con ccRCC con riesgo intermedio-alto o alto de recurrencia tras nefrectomía.
Basado en el ensayo multicéntrico LITESPARK-022, esta combinación demuestra:
✔️ Una reducción del 28% en el riesgo de recurrencia o muerte (HR = 0,72)
✔️ Una mejora estadísticamente significativa en la supervivencia libre de enfermedad (DFS)
💡 Un avance clave que consolida el valor de integrar terapias dirigidas con inmunoterapia en el escenario adyuvante temprano para reducir recaídas.
Infórmate aquí 👉 https://t.co/bcjl9tedAt
#Oncología #CáncerRenal #ccRCC #Inmunoterapia #FDA #OncoBites
ICYMI: Prognostic and Predictive Value of the Clearseq1–4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma https://t.co/QIeMBMP6B2 @eduardrssl @joniau @AbhishekDGarg @KU_Leuven #ccRCC #OpenAccess
💊#FDAApproval Update | The #FDA has approved #KEYTRUDA (#pembrolizumab) in combination with #WELIREG (#belzutifan) for the adjuvant treatment of patients with clear cell renal cell carcinoma (#ccRCC) at intermediate-high or high risk of recurrence following surgery.
💡The combination pairs PD-1 blockade with HIF-2α inhibition, targeting both anti-tumor immunity and a key driver of tumor hypoxia biology.
📊Phase 3 LITESPARK-022:
🔹Significant improvement in disease-free survival (DFS)
🔹28% reduction in the risk of recurrence or death vs pembrolizumab alone
🔹First approved adjuvant regimen combining a checkpoint inhibitor with a #HIF2α inhibitor in #RCC
#RenalCellCarcinoma #Oncology #CancerResearch #PharmaNews #MedicinalChemistry
🔎Drug resistance remains a major challenge in clear cell renal cell carcinoma. Our review summarizes the molecular mechanisms driving resistance and emerging therapeutic strategies to improve patient outcomes. #ccRCC
✍by Nicoletta Bianchi et al.
📌https://t.co/0zNeQA1qXL
#ASCO26 🚨 @DrChoueiri TiP: PEAK-1 is now actively enrolling globally in advanced #ccRCC.
This randomized phase 3 study is evaluating:
🔹 Casdatifan (next-generation HIF-2α inhibitor) + cabozantinib vs Placebo + cabozantinib
Key trial design:
🔹 N=720
🔹 2:1 randomization
🔹 Post-IO advanced/metastatic ccRCC
🔹 Prior anti–PD-1/PD-L1 required
Primary endpoint:
🔹 PFS by BICR
Secondary endpoints include:
🔹 OS
🔹 ORR
🔹 DOR
🔹 PROs
🌎 Enrollment ongoing across:
🇺🇸 🇨🇦 🇲🇽 🇦🇷 🇬🇧 🇪🇸 🇩🇪 🇮🇹 🇳🇱 🇨🇿 🇹🇷 🇯🇵 🇹🇼 🇦🇺
@UroToday @ASCO
@DrChoueiri exploratory @NateraOncology #ctDNA analysis of PhIII KN-564 trial of adj pembro in resected #ccRCC ➡️ baseline #ctDNA+ associated w/worse #DFS but DFS in favor of adj pembro, low sensitivity but high specific of assay in this population
#ASCO26 @OncoAlert
Le Ministre du Commerce Extérieur Julien PALUKU KAHONGYA @julienpalukucom a pris part au Forum International #RDC_Canada organisé conjointement par l'Ambassade de la RDC et le Conseil Canadien de Représentation des Communautés Congolaises(#CCRCC).
Au terme de deux jours d'échanges intenses à l'Université du Québec, les jalons d'un partenariat gagnant-gagnant sont posés. La mise en place d'une Task Force mixte témoigne de la volonté du Gouvernement congolais de sécuriser et d'accélérer les investissements canadiens dans les secteurs du numérique, de l'énergie verte et des ZES. #InvestInDRC #EconomicDiplomacy #AfricaMining #Sustainability @JdeQuebec
📺 Martin Voss, MD, of @MSKCancerCenter, discusses how findings from the phase 3 LITESPARK-011 trial help address ongoing unmet needs for patients with previously treated #ccRCC, as well as what the results suggest about combining HIF-2α inhibition with other agents, and key tolerability observations: https://t.co/oNemd0CpFr
ALL-IN-ONE: HIF2α —the full story in one review. From pseudohypoxia biology to clinical impact in VHL & ccRCC
⁉️What’s next? Smarter combinations, biomarkers and new indications—while tackling resistance & AEs
🔗 https://t.co/rjl6LvWCbW
@OncoAlert #ccRCC #HIF2a #CancerResearch
Happy to report our real-world analysis of ICI rechallenge in #ccRCC.
The interval since prior ICI may influence outcomes, highlighting that timing could be a key consideration in the design of future prospective trials.
Proud of our own @Anto_cigliola presenting a real-world data analysis of ICI rechallenge in #ccRCC
Adding to randomized clinical trial data
Despite the benefit is uncertain, time from previous ICI (6 months) may count
@ESMO_Open @myESMO @montypal @neerajaiims @SpiessPhilippe @NazliDizman @_alelarcher @u_capitanio @BrigidaMaiorano @CMercinelli @vale_tateo @OncoAlert @urotoday @SanRaffaeleMI @MyUniSR
A global real-world evidence study - ESMO Open https://t.co/61A37ohjXM
Proud of our own @Anto_cigliola presenting a real-world data analysis of ICI rechallenge in #ccRCC
Adding to randomized clinical trial data
Despite the benefit is uncertain, time from previous ICI (6 months) may count
@ESMO_Open @myESMO @montypal @neerajaiims @SpiessPhilippe @NazliDizman @_alelarcher @u_capitanio @BrigidaMaiorano @CMercinelli @vale_tateo @OncoAlert @urotoday @SanRaffaeleMI @MyUniSR
A global real-world evidence study - ESMO Open https://t.co/61A37ohjXM
🧬 Paraneoplastic syndromes in #RCC are not bystanders — they’re biology.
Two independent studies reveal a HIF-2 → PTHrP axis driving cachexia & hypercalcemia in #ccRCC, independent of tumor burden.
🔬 Key insights:
• HIF-2 directly activates PTHLH → ↑PTHrP → hypercalcemia & weight loss
• #Belzutifan rapidly ↓PTHrP & normalizes calcium (within days)
• Effects occur before tumor shrinkage → true on-target endocrine biology
• Not all tumors depend on HIF-2 → biological heterogeneity matters
• PTHrP emerges as a potential pharmacodynamic biomarker
💡 This reframes RCC:
👉 From tumor-centric → systemic HIF-2–driven disease
Are we underusing paraneoplastic signals to guide therapy? 👀
#KidneyCancer #HIF2 #Belzutifan #OncoTwitter #MedicalWatch
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.7M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.3M followers
Virat Kohli
@imvkohli
71.8M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.7M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers